Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.62 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179795 | 1.00 | HRH1 (0.62) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL232834 | 1.00 | HRH1 (0.62) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL27928248 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| Hydrochloric Acid SCHEMBL4374172 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| Hydrochloric Acid SCHEMBL16032107 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| Bromide SCHEMBL28648396 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL7417534 | 0.88 | HRH1 (0.68) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL4281797 | 0.88 | HRH1 (0.68) | HRH1RIPK1LMNAAOC3HTR2A | |
| Cadaverine Tartrate SCHEMBL9851431 | 0.88 | HRH1 (0.50) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL7373079 | 0.86 | HRH1 (0.59) | HRH1RIPK1LMNAAOC3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217415-B | Method for synthesizing chiral 3-amino-1-phenylpropanol and chiral 3- (methylamino) -1-phenylpropanol | 武汉大学 | 2024-06-18 | — | — | CN | claimed |
| CN-116217415-A | Method for synthesizing chiral 3-amino-1-phenylpropanol and chiral 3- (methylamino) -1-phenylpropanol | 武汉大学 | 2023-06-06 | — | — | CN | claimed |
| CN-110556578-A | Electrolyte additive, electrolyte containing electrolyte additive and application of electrolyte in lithium ion battery | FUJIAN INST RES STR MATTER CAS | 2019-12-10 | — | — | CN | claimed |
| CN-110297043-A | A kind of analysis method of 2- methylamino -1- phenyl-1-propanol | 上海医药工业研究院 | 2019-10-01 | — | — | CN | claimed |
| WO-2016065425-A1 | BIOTRANSFORMATION REACTIONS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-05-06 | — | — | WO | claimed |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-08-27 | — | — | US | claimed |
| EP-1765766-B1 | METHOD FOR PRODUCING ENANTIOMERS 3-HYDROXY-3-PHENYL-PROPYLAMINES | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-09-25 | — | — | EP | claimed |
| EP-2060559-A1 | Process for the preparation of enantiomerically pure 3-hydroxy-3-arylpropylamines and their optical stereoisomers | Cadila Pharmaceuticals Limited (IN) | 2009-05-20 | — | — | EP | claimed |
| CN-101400644-A | Processes for the preparation of atomoxetine hydrochloride | TEVA PHARM FINE CHEMICALS SRL (IT) | 2009-04-01 | — | — | CN | claimed |
| EP-2019679-A2 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | Theracos, Inc. (US) | 2009-02-04 | — | — | EP | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| WO-2000007976-A1 | FLUOXETINE PROCESS FROM BENZOYLACETONITRILE | SEPRACOR INC. (US) | 2000-02-17 | — | — | WO | claimed |
| US-6025517-A | Fluoxetine process from benzoylacetonitrile | SEPRACOR INC. (US) | 2000-02-15 | — | — | US | claimed |
| WO-1992004021-A1 | METHOD FOR PROVIDING IMPROVED ANALGESIC EFFECT | RICHARDSON VICKS INC. (US) | 1992-03-19 | — | — | WO | claimed |
| EP-0173928-B1 | CONTROLLED-RELEASE MEDICAL PREPARATIONS | AB LEO (SE) | 1990-06-13 | — | — | EP | claimed |
| CN-1042704-A | FLUOXETINE ANALOG | LILLY CO ELI (US) | 1990-06-06 | — | — | CN | claimed |
| US-4639368-A | CARBON DIOXIDE GENERATOR | FARMACON RESEARCH CORPORATION (US) | 1987-01-27 | — | — | US | claimed |
| EP-0173928-A1 | Controlled-release medical preparations | AB LEO (SE) | 1986-03-12 | — | — | EP | claimed |
| EP-0036145-B1 | AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1985-05-29 | — | — | EP | claimed |
| US-4416828-A | Process for the resolution of the racemate S-(carboxymethyl)-(RS)-cysteine (A) | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1983-11-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | HRH1 2838/4885RIPK1 1797/4885LMNA 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.